A61K 48/0041
The non-active part being polymeric
Official title: {the non-active part being polymeric}
A61K48/0041 (The non-active part being polymeric) appears on 554 US grants and 1,665 published applications in this corpus.
Search patents in A61K- Granted patents
- 554
- Published applications
- 1,665
- Assignees
- 649
- Inventors
- 3,396
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 3 | 0 |
| 2001 | 4 | 3 |
| 2002 | 9 | 15 |
| 2003 | 6 | 34 |
| 2004 | 5 | 34 |
| 2005 | 12 | 27 |
| 2006 | 10 | 39 |
| 2007 | 7 | 23 |
| 2008 | 9 | 22 |
| 2009 | 10 | 22 |
| 2010 | 14 | 29 |
| 2011 | 13 | 34 |
| 2012 | 13 | 19 |
| 2013 | 18 | 46 |
| 2014 | 26 | 55 |
| 2015 | 28 | 38 |
| 2016 | 27 | 40 |
| 2017 | 27 | 40 |
| 2018 | 22 | 54 |
| 2019 | 32 | 47 |
| 2020 | 24 | 54 |
| 2021 | 21 | 67 |
| 2022 | 33 | 93 |
| 2023 | 45 | 159 |
| 2024 | 39 | 220 |
| 2025 | 46 | 258 |
| 2026 | 51 | 193 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and materials for ameliorating creatine deficiency disorders6 Oct 2026US 12,751,995 B2The Regents of the University of California
- Methods of producing microbubble drug conjugates, viral gene therapy microbubble conjugates and targeted microbubbles29 Sep 2026US 12,746,292 B2
- DNA vector delivery using lipid nanoparticles29 Sep 2026US 12,746,293 B2NanoVision Therapeutics Inc.
- Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene29 Sep 2026US 12,747,430 B2Precision BioSciences, Inc.
- Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof15 Sep 2026US 12,735,459 B2Genzyme Corporation
- Adenovirus vector circular rna expression system8 Oct 2026US 2026/0306666 A1
- An intelligent charge switchable polymer-lipid hybrid system for in vivo delivery of molecules including rnas1 Oct 2026US 2026/0294830 A1Qurcan Therapeutics Inc.
- Compositions and methods for treatment of systemic lupus erythematosus1 Oct 2026US 2026/0295001 A1
- Modified aav vectors for gene therapy1 Oct 2026US 2026/0295079 A1The Trustees of Indiana University
- Lipids and nanoparticle formulations thereof1 Oct 2026US 2026/0295080 A1Arcturus Therapeutics, Inc.
Most cited
By later US patents
- RNA containing modified nucleosides and methods of use thereof353US 8,278,036 B2The Trustees of the University of Pennsylvania · 2012
- RNA containing modified nucleosides and methods of use thereof230US 8,691,966 B2The Trustees of the University of Pennsylvania · 2014
- RNA containing modified nucleosides and methods of use thereof222US 8,748,089 B2The Trustees of the University of Pennsylvania · 2014
- RNA containing modified nucleosides and methods of use thereof198US 8,835,108 B2The Trustees of the University of Pennsylvania · 2014
- Modified polynucleotides for the production of biologics and proteins associated with human disease196US 8,999,380 B2Moderna Therapeutics, Inc. · 2015